Kiniksa’s Heart’s Home Campaign Puts ARCALYST Growth Prospects In Focus

Kiniksa Pharmaceuticals International (NasdaqGS:KNSA) has launched Heart's Home, a direct to consumer campaign for ARCALYST.

Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis

Educational campaign to raise awareness of recurrent pericarditis and to empower patients to discuss ARCALYST with their ...
FierceBiotech

ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares

TARRYTOWN, N.Y., Feb. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol ...
EurekAlert!

Key clinical studies of Regeneron's ARCALYST (rilonacept) for treatment of CAPS published

Tarrytown, NY (August 11, 2008) – Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the publication of the results of three studies which supported the U.S. Food and Drug Administration ...
Monthly Prescribing Reference

Arcalyst Approved for Recurrent Pericarditis

Credit: Getty Images. Arcalyst is a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1. The Food and Drug Administration (FDA) has approved Arcalyst ® (rilonacept) ...
Monthly Prescribing Reference

Phase 3 trial of Arcalyst for prevention of gout flares

Regeneron announced that its Phase 3 study of Arcalyst (rilonacept injection) met its primary and secondary endpoints for the prevention of gout attacks. This trial, known as PRE-SURGE 1 (PREventative ...
Nasdaq

Can Growing Adoption Of Arcalyst Drive KNSA Stock Up?

(RTTNews) - Kiniksa Pharmaceuticals Ltd.'s (KNSA) flagship product Arcalyst has garnered widespread acclaim and acceptance since its launch in April 2021. With a growing adoption rate, the company has ...
Seeking Alpha

Kiniksa raises ARCALYST 2025 revenue guidance to $605M amid strong Q1 performance

CEO Sanj Patel highlighted that Kiniksa achieved $137.8 million in net product revenue for ARCALYST during Q1 2025, marking a 75% increase year-over-year. This success was attributed to robust ...
Seeking Alpha

Kiniksa: Steady Progress With Arcalyst, But Still Pretty Unexciting

I used to hold Kiniksa (KNSA) a few years ago, and also regularly covered it. I note from my past writings that my regular opinion about KNSA was that it was a solid but boring stock. That the stock ...
PharmaTimes

FDA queries safety of Regeneron’s Arcalyst for gout

Regeneron Pharmaceuticals saw its stock slip over the weekend after US regulators placed a question mark over the safety of Arcalyst in the gout setting. Regeneron Pharmaceuticals saw its stock slip ...
FierceBiotech

ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patien

TARRYTOWN, N.Y., Feb. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol ...